GlobeNewswire·Feb 23, 2026, 8:00 AM ET

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

Alps Group Inc. announced a peer-reviewed case study published in the February 2026 edition of SAGE Open Medical Case Reports.
The study involved nine nonconsecutive patients at ALPS Medical Centre who received autologous Natural Killer (NK) cell infusions between 2023 & 2024.
Data collection & analysis followed the Declaration of Helsinki & Malaysian Good Clinical Practice guidelines under National Medical Research Register ID 25-00333-MUM.
Patients were monitored for hematological parameters, liver function, hypersensitivity, inflammatory markers, & tumor markers to assess safety & toxic reactions.
The study provided evidence of clinical tolerability for NK cells cultured using the Company's proprietary, patent-pending antibody-free method.
Dr. Tham Seng Kong stated the NK cells appear safe & showed cytotoxicity toward cancer cell models in pilot cultures.
The antibody-free culture approach uses basic media & autologous plasma to enable cost-effective, large-scale production of highly pure NK cells.
Preliminary data supports the safety of this method & aims to guide future clinical investigations in broader patient populations.
The full study details are accessible via the provided SAGE Journals link.
Alps Group Inc. is the parent company of Alps Life Sciences Inc., focused on predictive, preventive, & precision medicine.